Date: 6th December, 2024

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 **Scrip Code: 539872**	**National Stock Exchange of India Limited** 5th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 **Symbol: BAJAJHCARE**

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 about API Manufacturing Site of Bajaj Healthcare Limited ("the Company") receiving approval from Therapeutic Goods Administration (TGA), Australia

This is to inform you that one of the Company's API Manufacturing Site situated at Block No. 588, Savli-Karachiya Road, At & Post: Gothada, Tal. Savli, Dist: Vadodara, Gujarat has received approval from Therapeutic Goods Administration (TGA), Australia. The said site has already received approval from USFDA (U.S. Food and Drug Administration) and EU.

This is another major milestone achieved for the site and the Company in achieving the vision of becoming a Global supplier of APIs. This recognition by TGA of Site's manufacturing and compliance capabilities would pave the path for direct supplies of API to this stringent regulated territory as well as supplies to drug product manufacturers across the globe, who are supplying their finished product in the territory of Australia and New Zealand.

Post this recognition, the Company expects to attract more CDMO contracts from existing and new clients.

The details as required under regulation 30 of SEBI (LODR) Regulation, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as "Annexure-I".

Kindly take the same on record.

Thanking You,

For and Behalf of Board of Director of
Bajaj Healthcare Limited

Apurva Bandivadekar

Digitally signed by Apurva Bandivadekar
Date: 2024.12.06 17:26:06 +05'30'

Apurva Bandivadekar
Company Secretary & Compliance Officer

Annexure-I

Details required under the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No	Particulars	Remarks
a)	Name of the regulatory or licensing authority	Therapeutic Goods Administration, Australia (TGA)
b)	Brief details of the approval~~/ license~~ obtained/ ~~withdrawn/ surrendered~~	The approval received from Therapeutic Goods Administration, Australia (TGA) for the Active Pharmaceutical Ingredient (API) manufacturing site situated at Savli, Vadodara, Gujarat
c)	Impact/relevance of such approval/~~license~~ to the listed entity	Direct supply of API to the territory of Australia & New Zealand.
d)	Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
e)	Period for which such approval/~~license~~ is~~/was~~ valid	24 Months
f)	The actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.	Not Applicable